Miromatrix Medical Opens New Headquarters and R&D Facility

Miromatrix Medical Inc., a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products for soft tissue reinforcement and advanced wound care,opened the doors to its new 12,000 square foot headquarters and R&D facility in Eden Prairie, MN.  With the acquisition of this new facility, the company’s Product Development, Sales & Marketing, Finance, and Clinical departments now all sit under one roof. 

In addition to serving as the company’s headquarters, the facility will be the center of Miromatrix’ efforts to create fully biological and transplantable organs.  The facility features a 2,000 square foot cleanroom suite, dedicated lab space for specific organs and bioreactors, custom deionized water system, various incubators, and a number of laminar flow hoods. 

Miromatrix Medical Launches MIROMESH® Biological Mesh

Miromatrix Medical Inc., a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products for soft tissue reinforcement, announced today the launch of MIROMESH®, the only biological mesh derived from whole compressed porcine livers for the reinforcement of soft tissue.

By using the whole liver, MIROMESH is able to retain the liver’s native architecture, vasculature, and tissue structure.  Other products on the market are derived from less vascular biological sources (dermis, small intestinal submucosa, pericardium, and bladder) and rely on immersion decellularization technology.  Miromatrix’ patented perfusion decellularization technology uses a different mechanism for decellularizing the source tissue, thereby allowing for the creation of the porcine liver-derived mesh, resulting in greater cellular infiltration compared to competing products derived from porcine dermis.

MIROMESH is available in a variety of sizes.

Miromatrix Medical Begins Manufacturing Operations in New Facility

Miromatrix Medical Inc., a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products for soft tissue reinforcement and advanced wound care, unveiled its new manufacturing facility about 50 miles from downtown Minneapolis.  The facility features an ISO Class 7 cleanroom suite, a state-of-the-art deionized water system, numerous laminar flow hoods, and an autoclave.  The cleanroom will be used to run Miromatrix’ perfusion decellularization process which is part of the manufacturing process for the company’s porcine liver-derived mesh products.  The facility will also house the company’s testing, release, warehouse, and distribution functions.

The facility has the capability to support the anticipated growth of the business.  Its proximity to the Twin Cities allows Miromatrix to tap into the strong medical technology and healthcare industry presence in the area.